Haemonetics (HAE) Asset Writedowns and Impairment (2013 - 2026)

Haemonetics' Asset Writedowns and Impairment history runs 13 years deep, the most recent figure standing at $77.2 million for Q1 2026.

• In Q1 2026, Asset Writedowns and Impairment changed N/A year-over-year to $77.2 million; the TTM figure through Mar 2026 stood at $95.1 million (changed N/A YoY), while the FY2026 annual figure was $86.5 million, up 3519.66% from the prior year.
• Asset Writedowns and Impairment was $77.2 million for Q1 2026 at Haemonetics, up from $9.3 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $77.2 million in Q1 2026 to a low of $94000.0 in Q3 2022.
• Historically, Asset Writedowns and Impairment has averaged $16.4 million across 4 years, with a median of $5.7 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Asset Writedowns and Impairment sank 98.17% in 2022, then slumped 81.74% in 2023.
• A 4-year view of Asset Writedowns and Impairment shows it stood at $94000.0 in 2022, then jumped by 445.74% to $513000.0 in 2023, then surged by 1712.87% to $9.3 million in 2025, then soared by 730.6% to $77.2 million in 2026.
• The last three Asset Writedowns and Impairment figures came in at $77.2 million (Q1 2026), $9.3 million (Q4 2025), and $8.6 million (Q3 2025), per Business Quant data.